Long-Acting anticholinergics in the treatment of asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 4, 2013, Pages 392-398

  Guyer, Autumn Chandler ^a   Long, Aidan Angelo ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticholinergics; Asthma; Ipratropium bromide; Severe asthma; Tiotropium bromide

Indexed keywords

ALKALOID; ATROPINE; ATROPINE METHYL NITRATE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LONG ACTING BETA 2 AGONIST; METHACHOLINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXITROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ASTHMA; AYURVEDA; BLOOD BRAIN BARRIER; BLURRED VISION; BRONCHODILATATION; CLOSED ANGLE GLAUCOMA; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HUMAN; MYDRIASIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SMOKING; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; MULTICENTER STUDIES AS TOPIC; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84880131922     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328362a775     Document Type: Review

References (37)

1. National Asthma E, Prevention P. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma: Summary Report 2007. J Allergy Clin Immunol 2007; 120:S94-S138.
2. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-938.
3. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, healthcare use, and mortality in the United States, 2001-2010. NCHS Data Brief 2012; 1-8.
4. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-413.
5. Gonem S, Desai D, Siddiqui S, Brightling CC. Evidence for phenotype-driven treatment in asthmatic patients. Curr Opin Allergy Clin Immunol 2011; 11: 381-385.
6. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
7. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006; 533: 36-39.
8. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161: 1862-1868.
9. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-Analysis. Thorax 2005; 60: 740-746.
10. Pedersen SE, Hurd SS, Lemanske RF Jr, et al., Global Initiative for A. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol 2011; 46: 1-17.
11. Tashkin DP, Celli B, Senn S, et al., Investigators U.S. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
12. Vogelmeier C, Hederer B, Glaab T, et al., Investigators P-C. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
13. Terzano C, Petroianni A, Ricci A, et al. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci 2004; 8: 259-264.
14. Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008; 102: 50-56.
15. Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008; 31: 1379-1380.
16. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450-504.
17. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975; 51: 13-20.
18. Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009; 22: 533-542.
19. Mullane K. The increasing challenge of discovering asthma drugs. Biochem Pharmacol 2011; 82: 586-599.
20. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005; 18: 264-272.
21. Adkinson NF, Middleton E. Middleton's allergy: principles and practice. 7th ed. Philadelphia, PA: Mosby/Elsevier; 2009.
22. Kapoor AS, Olsen SR, O'Hara C, et al. The efficacy of tiotropium as a steroidsparing agent in severe asthma. Can Respir J 2009; 16: 99-101.
23. Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009; 64: 778-783.
24. Fardon T, Haggart K, Lee DK, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007; 101: 1218-1228.
25. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-1726.
26. Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128: 315-322.
27. Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308-314.
28. Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181: 676-687.
29. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-Agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118-2125.
30. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207.
31. Bel EH. Tiotropium for asthma: promise and caution. N Engl J Med 2012; 367: 1257-1259.
32. Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011; 171: 914-920.
33. Oksuz H, Tamer C, Akoglu S, Duru M. Acute angle-closure glaucoma precipitated by local tiotropium absorption. Pulm Pharmacol Ther 2007; 20: 627-628.
34. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-Analysis of randomised controlled trials. Br Med J 2011; 342:d3215.
35. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 2009; 6: 256-259.
36. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-242.
37. Greenstone M. ACP Journal Club. Tiotropium improved lung function and delayed exacerbations in poorly controlled asthma. Ann Intern Med 2012; 157:; JC6-3.